NYMXFOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
NYMOX PHARMACEUTICAL CORP
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Sep 14, 2026
$0.04+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0491 (−53.90%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
NYMOX PHARMACEUTICAL CORP reported revenue of $0 for fiscal 2025. Free cash flow was -$1.81M.
Revenue
$0
FY2025
Operating income
-$3.68M
FY2025
Free cash flow
-$1.81M
FY2025
EPS, diluted
-$0.05
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$4.28M
- EPS, diluted
- -$0.05
- Free cash flow
- -$1.81M
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
$0
Gross profit
$0
Operating income
-$3.68M
Net income
-$4.28M
EPS, diluted
-$0.05
Free cash flow
-$1.81M
Reported period